Global E Online Ltd vs Revolution Medicines Inc. Common Stock — how do they compare? Global E Online Ltd trades at $39.99 (market cap $6.75B), while Revolution Medicines Inc. Common Stock trades at $191 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 6× Global E Online Ltd's market cap, and Revolution Medicines Inc. Common Stock is more actively traded (4,855,734 versus 1,468,708). Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| GLBE | RVMD | |
|---|---|---|
Market Cap | $6.75B | $40.32B |
Volume | 1,468,708 | 4,855,734 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $221.15 |
52-Week Low | $27.54 | $47.50 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $6.24B | $37.02B |
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.22, up 3.23% with strong analyst support (14 buys, 1 hold). The stock shows bullish technical momentum above key support at $40, while fundamentals reveal robust revenue growth from $962M in 2025 to $1.1B projected for 2026. Recent Q2 earnings beat expectations with 44% GMV growth, though insider selling and elevated P/E of 45.65 warrant caution.
Outlook remains positive given raised 2026 guidance and 28% upside to consensus target of $48.86. Key risks include valuation sensitivity to growth execution and persistent insider selling. The appointment of a new Chief Revenue Officer signals strategic focus on scaling, but investors should monitor quarterly execution against elevated expectations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →